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PreviewsInsulin biosynthesis: The IREny of it all
Recent studies have shown that the unfolded protein response (UPR) is essential for the survival of insulin-producing b cells.
Work in this issue of Cell Metabolism (Lipson et al., 2006) identifies a novel role for UPR activation in b cell function by
demonstrating that the UPR effector IRE1 is a positive regulator of glucose-stimulated proinsulin biosynthesis.Pancreatic islets of Langerhans are re-
sponsible for the homeostatic control of
glucose levels, maintaining them in a nar-
row range of 5w5.5 mM. This is accom-
plished by the secretion of endocrine
hormones such as insulin and glucagon
by b cells and a cells, respectively. Dia-
betes, and its attendant dysregulated
glucose levels, represents a family of
polygenic disorders caused by the ab-
sence of insulin production (autoimmune
or type 1 diabetes), insufficient produc-
tion of insulin, and/or inhibition of insulin
action at peripheral tissues such as fat,
liver, and muscle (type 2 diabetes). While
the release of endocrine hormones is
generally regulated by neuronal, nutri-
tional, and hormonal signals, the primary
regulatory signal for the secretion and
synthesis of insulin by b cells is consid-
ered to be glucose. The production and
release of insulin by b cells is tightly con-
trolled by transcriptional, translational,
and posttranslational mechanisms. A
paper in the current issue of Cell Metab-
olism (Lipson et al., 2006) provides
evidence supporting a novel role for
the endoplasmic reticulum-resident pro-
tein kinase inositol-requiring enzyme
(IRE) 1a in the selective regulation of
postprandial biosynthesis of insulin by
b cells.
The unfolded protein response (UPR)
is an evolutionarily conserved cellular re-
sponse that allows cells to survive the ac-
cumulation of unfolded proteins in the
ER. This UPR is tightly regulated by the
activity of three signal transducers, IRE
1, PERK, and ATF6 (Harding et al.,
2002; Zhang and Kaufman, 2006). The
resident ER chaperone BiP is thought
to be the primary regulator of the
UPR transducers (Zhang and Kaufman,
2006). In unstressed cells, BiP is bound
to each of the signaling transducers;
however, in response to ER stress or pro-
tein overload, BiP is released, allowing it
to assist in the proper folding of ER pro-
teins. This also allows IRE1 and PERK
to be activated by homodimerization
and autophosphorylation. The activation
of ATF6 occurs in the golgi, where it isCELL METABOLISM 4, 175–183, SEPTEMBERcleaved to an active transcription factor
that translocates to the nucleus.
The three signal transducers have dif-
ferent modes of action. Activated PERK
attenuates general protein synthesis by
phosphorylating the transcriptional elon-
gation factor eIF2a and participates in
the transcriptional activation of UPR-
associated genes (Harding et al., 2002;
Zhang and Kaufman, 2006). IRE1 con-
tains not only a kinase domain but also
an endoribonuclease domain that when
activated mediates the site-specific
splicing of a 26 base intron of X-box pro-
tein-1 (XBP-1). This splice produces
a frameshift in XBP-1 mRNA leading to
the synthesis of a potent transcription
factor that regulates the expression of
various genes involved in the degrada-
tion of unfolded proteins, or proper pro-
tein folding (Harding et al., 2002; Zhang
and Kaufman, 2006).
b cells are highly sensitive to alter-
ations in the activity of the UPR. Muta-
tions in PERK have been identified in
Wolcott-Rallison syndrome, an autoso-
mal recessive disease characterized by
a number of disorders, including diabe-
tes that is due to selective dystrophy of
b cells (Delepine et al., 2000). PERK-defi-
cient mice develop diabetes by 2–4
weeks of age due to progressive b cell
loss (Harding et al., 2001; Zhang et al.,
2002), and mice expressing a Ser51Ala
mutation at the PERK phosphorylation
site in eIF2a show a loss of b cell mass
in utero (Scheuner et al., 2001). While
these studies provide evidence that
UPR, or more specifically PERK, signal-
ing is essential for b cell survival, few
studies have examined the role of IRE1
in regulating pancreatic b cell function
or survival.
Lipson et al. now show that glucose
stimulates IRE1a phosphorylation in iso-
lated mouse islets and insulinoma cells
in a concentration-dependent fashion
that correlates with the stimulatory ef-
fects of glucose on insulin secretion.
While IRE1a phosphorylation correlates
with glucose-stimulated insulin secre-
tion, IRE1a depletion using siRNA or ex-2006 ª2006 ELSEVIER INC.pression of a kinase-dead IRE1 mutant
fails to modify the stimulatory actions of
glucose on insulin secretion or insulin
transcription by INS-1 cells. Instead,
IRE1a appears to selectively regulate
the translation of insulin, as proinsulin
biosynthesis is significantly reduced
while total protein synthesis is unaffected
in INS-1 cells depleted of IRE1a by siRNA
knockdown. These novel findings sug-
gest that IRE1amay function as apositive
and selective regulator of insulin biosyn-
thesis in response to glucose challenge.
These findings are in contrast to the
more global inhibitory actions of PERK-
mediated eIF2a phosphorylation as a
negative regulator of protein translation
(Zhang and Kaufman, 2006).
IRE1 posseses both a kinase and ribo-
nuclease activity that are activated fol-
lowing its dissociation from BiP. While
glucose stimulates IRE1a phosphoryla-
tion, it fails to stimulate XBP-1 splicing
(ribonuclease activity), the dissociation
of IRE1a from BiP, or the activation of
JNK, a downstream target whose activa-
tion is associated with cell death under
conditions of prolonged UPR activation
(Urano et al., 2000). This novel form of
IRE1a regulation, which the authors
term ‘‘Stimulus-Coupling Adaptation to
ER Folding’’ or SCAEF, may serve as a
physiological regulator of specialized
secretory cells types such as b cells,
which produce specific proteins such
as insulin. This form of IRE1a regulation
also differs from the more classical acti-
vation under conditions of severe ER
stress wherein IRE1 dissociates from
BiP resulting in the activation of both ri-
bonuclease and kinase activity. While
others have shown that it is possible to
activate BiP-associated IRE1 under con-
ditions of mild ER stress (Credle et al.,
2005), the current findings describe
a physiological regulatory mechanism
by which the selective regulation of
IRE1a kinase activity participates in a
specific cellular function, in this case in-
sulin biosynthesis. In contrast to the tran-
sient and selective activation of IRE1a
kinase activity in response to elevated175
P R E V I E W SFigure 1. Differential regulation of IRE1a in pancreatic b cells in response to an acute or chronic glucose
exposure
In response to an acute exposure (1 hr) to stimulatory concentrations of glucose, IRE1a remains bound to BiP;
however, it is phosphorylated and functions to stimulate proinsulin translation. In contrast, in response to
a chronic exposure (3–7 days) to elevated levels of glucose, IRE1a is fully activated as it is likely released from
BiP, is phosphorylated, and stimulates XBP-1 splicing. Chronic exposure to elevated levels of glucose results
in b cell death or glucotoxicity.concentrations of glucose that occurs in
response to an acute challenge, chronic
exposure of b cells to elevated levels of
glucose (25 mM) for 3 and 7 days results
in a severe stress that is associated with
the activation of both IRE1a kinase and
ribonuclease activity. These chronic glu-
cose exposure conditions are known
to stimulate b cell death by a process
termed glucotoxicity (Leahy, 2005; Rob-
ertson et al., 2004). These findings sug-
gest that the normal physiological re-
sponse of IRE1a in b cells to an acute
glucose challenge is the selective activa-
tion of its kinase activity and the positive
regulation of proinsulin biosynthesis
(Figure 1). However, under pathophysio-
logical conditions or severe stress as
observed during chronic exposure of
b cells to elevated levels of glucose,
IRE1a kinase and endoribonuclease
activity is stimulated, and this may con-
tribute to b cell failure (or glucotoxicity).
These provocative findings of Lipson
et al. suggest that IRE1a may function
as a positive regulator of insulin biosyn-
thesis, yet the mechanisms responsible
for glucose-stimulated IRE1a kinase ac-176tivity remain unclear. Glucose-induced
IRE1a phosphorylation is attenuated by
2-deoxyglucose, suggesting that glu-
cose metabolism is required for IRE1a
activation. However, IRE1a is also phos-
phorylated in response to secretagogues
that function by directly depolarizing
b cells (arginine and KCl) and by agents
that augment insulin secretion via cAMP
(GLP-1). Intriguingly, this suggests the
existence of multiple mechanisms of
IRE1a activation, which may include
roles for elevations in intracellular cal-
cium as well as the activation of cAMP-
dependent pathways. Arginine, KCl,
and glucose (via metabolism and closure
of ATP channels) stimulate insulin secre-
tion by depolarizing b cells, allowing for
calcium entry and calcium-mediated
exocytosis. A speculated mechanism
might include a hypothetical (novel, or
existing) kinase capable of coupling in-
tracellular information provided by secre-
tagogue stimulation of b cells (i.e., cal-
cium or cAMP accumulation) with the
phosphorylation of IRE1a and the induc-
tion of proinsulin biosynthesis. Future
studies designed to identify the mecha-nisms by which this diverse and mecha-
nistically distinct series of secretagogues
selectively activate IRE1a kinase activity
independent from its ribonuclease ac-
tivity are likely to provide new insights
into additional cellular and physiological
functions of IRE1 and alternative mecha-
nisms by which IRE1 may be regulated
under conditions of ER stress.
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